Wegovy Shakes Up Weight Loss Market: Novo Nordisk Cuts Ties with Telehealth Partner and Unveils Promising New Research
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Wegovy Shakes Up Weight Loss Market: Novo Nordisk Cuts Ties with Telehealth Partner and Unveils Promising New Research
-
Narrated by:
-
By:
About this listen
Join veteran global reporter Alexandra Reeves as she unpacks the latest dramatic developments in the world of obesity treatment. In this must-listen episode, discover why pharmaceutical giant Novo Nordisk abruptly ended its partnership with telehealth provider Hims and Hers over allegations of counterfeit Wegovy products. Learn about groundbreaking clinical research unveiled at the American Diabetes Association summit, including Eli Lilly's bimagrumab combination therapy that preserves muscle while maximizing fat loss. Alexandra explores Wegovy's higher-dose formulation showing 21% average weight loss, important safety considerations, and what these developments mean for millions seeking effective obesity treatments. From corporate battles to scientific breakthroughs, this comprehensive analysis brings clarity to a medication that's reshaping modern medicine. Perfect for healthcare professionals, investors, and anyone interested in the future of weight management and pharmaceutical innovation.
No reviews yet